Medine.co.uk

Avipro Ibd Xtreme Lyophilisate For Suspension


Revised: March 2015

AN: 00880/2014


SUMMARY OF PRODUCT CHARACTERISTICS


1. NAME OF THE VETERINARY MEDICINAL PRODUCT


AviPro IBD Xtreme

(alternative FR: AviPro IBD X, ES: AviPro IBDX, HU: AviPro IBD X vakcina A.U.V.)

Lyophilisate for suspension


2. QUALITATIVE AND QUANTITATIVE COMPOSITION


Active substance:

1 dose contains 101.5- 103.0EID50* live intermediate plus IBD (Infectious Bursal Disease) virus, strain V217.

*EID50= 50 % embryo infective dose: the virus titre required to infect 50 % of the inoculated embryos.

Host system: embryonated SPF-hen´s eggs


Excipient(s):

For a full list of excipients, see section 6.1.


3. PHARMACEUTICAL FORM


Lyophilisate for suspension.

Appearance: rose to red brown lyophilisate


4. CLINICAL PARTICULARS


4.1 Target species


Chickens (from 7 days old)


4.2 Indications for use, specifying the target species


For active immunisation of chickens with maternally derived antibodies (breakthrough titre: 636) to reduce clinical disease, weight loss and acute lesions of the bursa of Fabricius associated with infection caused by very virulent avian Infectious Bursal Disease (IBD) viruses.


Onset of protection: 2 weeks.

Duration of immunity: 12 weeks based on serology


4.3 Contraindications


Do not use in unhealthy birds.


4.4 Special warnings for each target species


As described under 4.6.



4.5 Special precautions for use


Special precautions for use in animals

The vaccine strain may spread to unvaccinated chickens, since it is excreted via the faeces for at least 9 days. Avoid spreading to laying hens, birds approaching lay and young birds below 7 days of age.

The vaccine should not be used in birds without maternally derived antibodies. Spread of the vaccine strain to such birds should be prevented.

This vaccine induces serious and prolonged lesions in the bursa of Fabricius. It should therefore only be used to compete with very virulent (vv) IBD virus infection or to induce immunity in the face of still high maternally derived antibody (MDA) levels (breakthrough ELISA titre 636), where vaccines containing mild and intermediate strainshave appeared to be insufficient.

MDA levels may differ throughout a given population. Therefore, depending on age and genetic factors of the birds IBD-like symptoms or mortality may occur in animals with low MDA level or without MDAs.


Special precautions to be taken by the person administering the veterinary medicinal product to animals

Wash and disinfect hands and equipment after vaccinating.


4.6 Adverse reactions (frequency and seriousness)


On day 7 post vaccination severe lymphocyte depletion is seen in the bursae of the majority of birds. Lymphocyte repopulation commences after day 7 post vaccination but by day 28 post vaccination notable lesions still remain in the bursae of the birds.


4.7 Use during pregnancy, lactation or lay


Do not use in birds in lay or close to the onset of lay.


4.8 Interaction with other medicinal products and other forms of interaction


No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.


4.9 Amounts to be administered and administration route


One dose should be administered per chicken in the drinking water after resuspension.


Vaccination programme

The determination of the vaccination date depends on a number of factors including status of maternal antibodies, type of bird, infection pressure, housing and management conditions.

AviPro IBD Xtreme can break through a maternal ELISA-antibody level of 636.

Homogenous levels of MDA levels facilitate a more accurate timing of the vaccination.

To predict the age, when MDA have sufficiently decreased to allow effective vaccination it is advised, to test serum samples of at least 20 chicks by serology and apply the “Deventer Formula” for intermediate plus vaccines.


According to this formula the optimum age of vaccination is as follows:

Decide what percentage of the flock shall be representing and remove the highest titres that are excluded (e.g. 75 % of the flock; remove the highest 25 % of the titres).

Calculate the mean ELISA antibody titre of these birds.

Vaccination age = {(log2 titre bird % - log2 breakthrough) x t_} + age at sampling
+ correction 0-4
(Bird % = ELISA titre of the bird representing a certain percentage of the flock

t_ = half-life time (ELISA) of the antibodies in the type of chickens being sampled

Age sampling = age of the birds at sampling

Correction 0-4 = extra days when the sampling was done at 0 to 4 days of age)


Birds should be at least 7 days of age at vaccination. The optimum age for vaccination may be calculated using the level of maternal antibody in the chicks at day old (Deventer formula), but normally lies in the range 12-21 days. Additional information on application and disease control is available from Lohmann Animal Health.


Ensure that the drinking water is cold, clean, non-chlorinated and free from detergents, disinfectants and metal ions.


Drinking water application:

Determine the number of vaccine doses and amount of water (see below) required. Do not split large vials to vaccinate more than 1 house or drinking system, as this may lead to mixing errors.

Ideally vaccine should be administered in the volume of water consumed by the birds in up to 2 hours. As a general rule, apply reconstituted vaccine to cold and fresh water at the rate of 1,000 doses of vaccine to 1 litre of water per day of age for 1,000 chickens, e.g. 10 litres would be needed for 1,000, 10 day old chickens. Under hot climates or with heavy breeds this amount may have to be increased up to a maximum of 40 litres per 1,000 birds. If in doubt, measure water intake the day before administering vaccine.
– Administer the reconstituted vaccine to birds immediately.
– Make sure that birds do not have access to unmedicated water during vaccination.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary


No other signs have been observed as described under 4.6 following administration of a ten-fold dose.


4.11 Withdrawal period(s)


Zero days.


5. IMMUNOLOGICAL PROPERTIES


Pharmacotherapeutic group: avian infectious bursal disease virus (Gumboro disease),

ATCvet code: QI01AD09

The active ingredient of the lyophilisate is a live intermediate plus Infectious Bursal Disease-virus strain V217 which stimulates active immunity against IBD-virus.

The strain causes an average score of bursal lesion of 2.9 (out of 5 according to Ph Eur) at 21 days post vaccination.


6. PHARMACEUTICAL PARTICULARS


6.1 List of excipients


Disodium phosphate dihydrate

Lactose monohydrate

Potassium dihydrogen phosphate

Skim milk powder


6.2 Incompatibilities


Do not mix with any substances other than water or skimmed milk.


6.3 Shelf life


Shelf life of the veterinary medicinal product as packaged for sale: 21 months

Shelf life after reconstitution according to directions: 2 hours


6.4 Special precautions for storage


Store in a refrigerator (2 °C – 8 °C).Do not freeze.Protect from direct sunlight.

Protect the reconstituted vaccine from direct sunlight and temperatures of above 25 °C.Do not freeze.


6.5 Nature and composition of immediate packaging


Nature of primary packaging elements:


The vaccine is available in the following packaging sizes:

Box containing 1 or 10 vials with 500 / 1,000 / 2,500 / 5,000 / 10,000 doses per vial.


Not all pack sizes may be marketed.


6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products


Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.


7. MARKETING AUTHORISATION HOLDER


Lohmann Animal Health GmbH

Heinz – Lohmann-Str. 4

27472 Cuxhaven

Germany


8. MARKETING AUTHORISATION NUMBER


Vm16894/4006


9. DATE OF FIRST AUTHORISATION


29 May 2008


10. DATE OF REVISION OF THE TEXT


March 2015






Approved: 16 June 2015


Page 5 of 5